Table 3 Short-term clinical outcomes of pancreatitis by treatment for immune checkpoint inhibitor-induced pancreatic injury
From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Outcome | Steroids, no. (%) | Intravenous fluids, no. (%) | ||||
|---|---|---|---|---|---|---|
Steroids, n = 31 | No steroids, n = 51 | P | Intravenous fluids, n = 32 | No intravenous fluids, n = 50 | P | |
Mean time from peak lipase value to improvement to grade 1a (standard deviation) | 55 days (11) | 48 days (7) | 0.711 | 55 days (51) | 52 days (49) | 0.850 |
Mean duration of symptomsb (standard deviation) | 5 days (3) | 4 days (2) | 0.824 | 4 days (3) | 5 days (3) | 0.650 |
Pseudocyst | 1 (3) | 2 (4) | 1.000 | 3 (9) | 0 (0) | 0.056 |
Hospitalization | 6 (19) | 9 (18) | 1.000 | 14 (44) | 1 (2) | <0.001 |
Mean duration of hospitalization (standard deviation) | 4 days (3) | 5 days (2) | 0.762 | 5 days (3) | 1 day (-) | 0.166 |
Intravenous fluids | 14 (45) | 18 (35) | 0.484 | - | - | - |
Steroids | - | - | - | 14 (44) | 17 (34) | 0.484 |
Immune checkpoint inhibitor therapy interrupted | 18 (58) | 29 (57) | 1.000 | 22 (69) | 25 (50) | 0.113 |